… To determine the combinational effects of EGFR TKIs and chemotherapeutic drugs in vitro,
we first treated lung cancer cells harboring either mt EGFR (H3255, PC9) or WT EGFR (A549, …

… 5,000 lung cancer cells forms colonies in soft agar assay, indicating that not every lung cancer
cell is capable of tumor … the notion that lung adenocarcinoma arises from stem cells in the …

… in squamous cell carcinomas. Equivocal data (with some positive studies but other negative
… have generally not proven clinically useful in lung cancer, although small randomized trials …

… cell growth arrest have not been elucidated. Here, we describe miR-340 as a novel tumor
suppressor in non-small cell lung cancer … growth-inhibitory and proapoptotic effects of miR-340 …

… To determine how SCLC tumour cells can affect immune system responses, we investigated
the effects of tumour cell lines on CD4 + T cells isolated from healthy human blood and …

… control and Negative control 2 is miRNA mimic negative … on the malignant phenotype of lung
cancer cells makes it … levels of miR-146a in cancer cells could be explored therapeutically. …

… Aspects of this heterogeneity have been implicated in tumour evolution, metastasis and
acquired therapeutic resistance. Although clinical progress in SCLC treatment has been …

… disease to review and possibly improve therapeutic treatment options. Surgery, radiation, …
used to treat lung cancer. However, these treatment types may cause different side effects, and …

The incidence and mortality of small-cell lung cancer worldwide make this disease a notable
health-care issue. Diagnosis relies on histology, with the use of immunohistochemical …

… Because erlotinib cannot induce G 1 -phase arrest in tumors harboring K-Ras mutations,
continuous daily erlotinib should have a minimal negative effect on the cytotoxicity of …